Details for Patent: 7,498,440
✉ Email this page to a colleague
Which drugs does patent 7,498,440 protect, and when does it expire?
Patent 7,498,440 protects ANORO ELLIPTA, INCRUSE ELLIPTA, and TRELEGY ELLIPTA, and is included in three NDAs.
This patent has sixty-one patent family members in thirty-six countries.
Summary for Patent: 7,498,440
| Title: | Muscarinic acetylcholine receptor antagonists |
| Abstract: | Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided. |
| Inventor(s): | Laine; Damane I. (King of Prussia, PA), Palovich; Michael R. (King of Prussia, PA), McCleland; Brent W. (King of Prussia, PA), Neipp; Christopher E. (King of Prussia, PA), Thomas; Sonia M. (King of Prussia, PA) |
| Assignee: | Glaxo Group Limited (Greenford, Middlesex, GB) |
| Application Number: | 11/568,330 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Delivery; |
Drugs Protected by US Patent 7,498,440
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 203975-001 | Dec 18, 2013 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Glaxo Grp England | INCRUSE ELLIPTA | umeclidinium bromide | POWDER;INHALATION | 205382-001 | Apr 30, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 209482-001 | Sep 18, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| Glaxosmithkline | TRELEGY ELLIPTA | fluticasone furoate; umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 209482-002 | Sep 9, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 7,498,440
| PCT Information | |||
| PCT Filed | April 27, 2005 | PCT Application Number: | PCT/US2005/014386 |
| PCT Publication Date: | November 10, 2005 | PCT Publication Number: | WO2005/104745 |
International Family Members for US Patent 7,498,440
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 1740177 | ⤷ Sign Up | C300694 | Netherlands | ⤷ Sign Up |
| European Patent Office | 1740177 | ⤷ Sign Up | CA 2014 00052 | Denmark | ⤷ Sign Up |
| European Patent Office | 1740177 | ⤷ Sign Up | PA2014038 | Lithuania | ⤷ Sign Up |
| European Patent Office | 1740177 | ⤷ Sign Up | 92565 | Luxembourg | ⤷ Sign Up |
| European Patent Office | 1740177 | ⤷ Sign Up | 1490060-9 | Sweden | ⤷ Sign Up |
| European Patent Office | 1740177 | ⤷ Sign Up | 14C0075 | France | ⤷ Sign Up |
| European Patent Office | 1740177 | ⤷ Sign Up | C20140032 00132 | Estonia | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
